Irish journal of medical science · 2025
The expression trend and regulatory role of miR-484 in patients with gestational diabetes mellitus.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hou Yan, Wan Li, Long Lijia
Аннотация
OBJECTIVE: Gestational diabetes mellitus (GDM) is characterized by the onset of abnormal glucose metabolism during pregnancy. This study aims to examine the expression patterns and functional significance of miR-484 in GDM.
METHODS: The levels of miR-484 in GDM patients were compared to those in normal pregnant women through RT-qPCR. Subsequently, the diagnostic and predictive capacity of miR-484 for GDM was assessed utilizing Receiver Operating Characteristic (ROC) curve. In the next phase, the effects of miR-484 on blood glucose levels and insulin resistance in GDM mice were studied by establishing a GDM mouse model. Finally, pancreatic tissues were isolated to elucidate the influence of miR-484 on inflammation processes and oxidative stress.
RESULTS: Elevated levels of miR-484 have been observed in GDM patients, demonstrating a positive correlation with blood glucose levels. ROC curve analysis indicated that miR-484 possesses substantial diagnostic and predictive capabilities for GDM, with an AUC of 0.835, a sensitivity of 80.95%, and a specificity of 82.00%. Furthermore, in GDM models, the downregulation of miR-484 significantly mitigated the adverse effects associated with GDM, leading to notable reductions in blood glucose levels and insulin resistance. Following the down-regulation of miR-484, a notable reduction in the levels of IL-1β, TNF-α, IL-6, and MDA in the pancreas was also observed. Concurrently, there was a significant increase in the levels of SOD and CAT.
CONCLUSION: miR-484 might act as a biomarker for the early-stage recognition of GDM. Down-regulating this molecule is beneficial for lowering blood glucose, insulin resistance, and pancreatic inflammation or oxidative stress.
METHODS: The levels of miR-484 in GDM patients were compared to those in normal pregnant women through RT-qPCR. Subsequently, the diagnostic and predictive capacity of miR-484 for GDM was assessed utilizing Receiver Operating Characteristic (ROC) curve. In the next phase, the effects of miR-484 on blood glucose levels and insulin resistance in GDM mice were studied by establishing a GDM mouse model. Finally, pancreatic tissues were isolated to elucidate the influence of miR-484 on inflammation processes and oxidative stress.
RESULTS: Elevated levels of miR-484 have been observed in GDM patients, demonstrating a positive correlation with blood glucose levels. ROC curve analysis indicated that miR-484 possesses substantial diagnostic and predictive capabilities for GDM, with an AUC of 0.835, a sensitivity of 80.95%, and a specificity of 82.00%. Furthermore, in GDM models, the downregulation of miR-484 significantly mitigated the adverse effects associated with GDM, leading to notable reductions in blood glucose levels and insulin resistance. Following the down-regulation of miR-484, a notable reduction in the levels of IL-1β, TNF-α, IL-6, and MDA in the pancreas was also observed. Concurrently, there was a significant increase in the levels of SOD and CAT.
CONCLUSION: miR-484 might act as a biomarker for the early-stage recognition of GDM. Down-regulating this molecule is beneficial for lowering blood glucose, insulin resistance, and pancreatic inflammation or oxidative stress.